(Forbes) Bill Ackman and Chipotle Mexican Grill CMG +1.39% have a lot in common. After all, both have suffered a bruising 12-month stretch in which their futures came into serious question and many investors remain skeptical about a comeback.
Ackman’s troubles stem from a $4 billion bet on Valeant Pharmaceuticals VRX +2.47%, which backfired amid an accounting and price gouging scandal that caused the company’s stock to drop over 80% between September 2015 and January 2016. Chipotle, by contrast, had a norovirus outbreak at two of its stores in 2015 that caused first quarter same-store sales to plunge 30% and the company’s stock to drop over 40%.
